ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

An Orally-Bioavailable Glutathione-Based Hepatoprotective Compound in Experimental Acute Liver Injury: More Effective than Silymarin and YHK

Kantah MK1, Kumari A2, He F3, Sollano J4, Alagozlu H5, Min CH1, Lorenzetti A1, Morita Y1 and Marotta F1,6*

1ReGenera Research Group for Aging-Intervention, Milano, Italy

2Institut de Biologie Intégrative et des Systèmes, Université Laval, Québec, QC, Canada

3Department of Nutrition and Food Hygiene, West China School of Public Health, Sichuan University, China

4Gastroenterology Department, University of Santo Tomas, Manila, The Philippines

5Medical Park Ankara Hospital, Gastroenterology Department, Ankara,Turkey

6Milano Medical-Gender Healthy Aging Unit by Genomics & Biotechnology, Milano, Italy

*Corresponding Author:
Prof. Francesco Marotta, MD, PhD
Milano Medical-Gender Healthy Aging Unit by Genomics and Biotechnology
Piazza Firenze, 12, 20154 Milano, Italy
E-mail: fmarchimede@libero.it

Received date: May 10, 2016; Accepted date: July 19, 2016; Published date: August 9, 2016

Citation: Kantah MK, Kumari A, He F, Sollano J, Alagozlu H, et al. (2016) An Orally-Bioavailable Glutathione-Based Hepatoprotective Compound in Experimental Acute Liver Injury: More Effective than Silymarin and YHK. J Gastrointest Dig Syst 6:462. doi:10.4172/2161-069X.1000462

Copyright: © 2016 Kantah MK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.

Abstract

Many hepatoprotective non-chemical preparations have been recommended as complementary medicine for the treatment of liver disorders. We have utilized a well-defined model of liver injury to study the efficacy of GLU-9599 (a oral bioavailable glutathione-based compound added with selenium, L-cysteine and vitamin C) designed to support liver detox function. Wistar albino rats were divided into five groups. Group I represented the healthy control group; Groups II-IV were given carbon tetrachloride (CCl4) intragastrically. Rats were exposed to CCl4 after they had been pretreated for five days with either saline, silymarin extract, YHK (am herbal Japanese compound with putative hepatoprotective effects) or GLU-9599. After inducing hepatic damage, Group II served as control CCl4; Group III and IV were given silymarin (reference hepatoprotective) and YHK whereas Groups V was administered GLU-9599. Animals were sacrificed 24 hours after receiving CCl4. Liver enzymes and hepatic histology formed the basis for evaluating the efficacy of the treatments. Samples of livers were observed under microscope and electron microscopy (TEM) for the histopathological changes. Levels of marker enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) significantly increased in CCl4 treated rats (Group II). Groups III, IV and V intoxicated with CCl4 and treated with the above hepatoprotective agents showed a significant decrease of the activities of these two enzymes (p<0.05). However, GLU-9599 provided a significantly stronger effect than YHK (p<0.05) and a trend improvement as compared to sylimarin. This was confirmed at histology and TEM whereas the others hepatoprotective compounds had only limited benefits on morphological abnormalities. In conclusion GLU-9599 could be a promising hepatoprotective compound of safe profile although extensive clinical studies are warranted.

Keywords

Top